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Abstract 
 
The treatment of multiple myeloma (MM) has been markedly altered by the clinical use of 
proteasome inhibitors and immunomodulatory drugs (IMiDs). Afuresertib (AFU), a novel 
inhibitor of the serine/threonine kinase AKT, shows clinical efficacy as a monotherapy against 
hematological malignancies and is expected to be used in combination with standard 
therapies for MM. To develop a more effective and less toxic combination of IMiDs for therapy, 
we examined the anti-tumor effect of sub-optimal doses of AFU, pomalidomide plus 
dexamethasone (PD), and the AFU-PD combination on MM cells. Two MM cell lines, XG-7 
and U266, with low sensitivity to both PD and AFU monotherapies, were subjected to these 
combinations and analyzed. Although the cell lines showed a slight reduction in viability with 
the sub-optimal doses of each monotherapy, the combination of the treatments resulted in a 
reduction in cell viability and the progression of apoptosis. Co-treatment with sub-optimal 
doses of PD and AFU enhanced caspase activation and highly suppressed the expression of 
IKZF1 and IKZF3. In addition, this combination promoted the dephosphorylation and 
stabilization of 4EBP1, an inhibitor of eIF4E activation, which led to the impairment of 
eIF4E-mediated translational activity. Furthermore, AFU showed a sufficient inhibitory 
effect on the phosphorylation of FOXO1, a tumor suppressor, in monotherapy or in 
combination with PD, which may be attributable to the activation of FOXO1, the subsequent 
inhibition of tumor growth, and the induction of cell death. In conclusion, the combination 
therapy with sub-optimal doses of PD and AFU exhibited potent anti-tumor activity in MM 
cells and may provide a novel strategy for the treatment of patients who experienced 
intolerable toxicity or insufficient response during IMiD therapy. 
